AI News · The messy stuff ·
WHO calls for stronger ethical oversight of AI in health research
The World Health Organization called for stronger ethical oversight of AI in health research, according to a World Economic Forum roundup. WHO warned that the speed of innovation must not outpace safeguards. Its concerns include human rights, equity and privacy.
Key points
- WHO called for stronger ethical oversight of AI throughout the health research lifecycle.
- Its concerns include human rights, equity, privacy and public trust.
- Research ethics committees need greater expertise, training and resources, WHO said.
- The appeal includes researchers, regulators, funders and publishers, as well as ethics committees.
- Industry projections of faster, cheaper drug development remain forecasts, not established results.
What happened: The World Health Organization has called for stronger ethical oversight of artificial intelligence in health research, warning that innovation must not outpace protections for human rights, equity, privacy and public trust. According to a World Economic Forum health roundup, a new WHO report urges closer scrutiny throughout the research lifecycle. The call puts responsible use alongside the drive to develop and deploy AI tools, rather than treating safeguards as a final check before use.
The details: The WHO’s appeal extends beyond researchers to ethics committees, regulators, funders and publishers. The organization is asking these groups to strengthen oversight so that AI-enabled health research is conducted responsibly and benefits everyone. Research ethics committees, in particular, will need greater expertise, training and resources, the WHO said. Their assessments must address transparency, bias, accountability and potential harms. The organization highlighted these needs as AI tools are deployed more widely, but unevenly, across health systems around the world.
Background: The push for stronger safeguards comes as AI use expands across healthcare, from diagnostics to drug development. The World Economic Forum reported that pharmaceutical companies are increasing investment in tools intended to accelerate drug discovery, design molecules and streamline clinical-trial planning. Industry forecasts cited by Reuters suggest machine learning could halve early-stage drug-development costs and timelines within three to five years. Those figures are forecasts, not established results. Partnerships between technology and pharmaceutical companies since the beginning of 2025 further illustrate the sector’s momentum.
Who it affects: For health research teams choosing or using AI, the WHO’s emphasis is on scrutiny across the research process, not only at deployment. Ethical review and privacy safeguards belong within that process rather than being added afterward. The breadth of the appeal also matters: the WHO is calling on those who fund, review, regulate and publish research to participate, rather than placing responsibility solely on developers or individual researchers. Its warning about uneven deployment makes equity a central concern alongside privacy and potential harm.
What to watch: The practical question is how oversight bodies will gain the expertise and resources the WHO says they need. A funding commitment or implementation timetable was not reported. Separately, European Commission President Ursula von der Leyen has argued that AI should support, rather than replace, clinicians. She said it could help doctors access information for diagnosis and treatment faster, while stressing that patients should not receive major medical decisions from a machine.
Our take
Health research teams should treat ethical review and privacy safeguards as part of AI deployment, not as checks added afterward.